Lyme Disease Ld Market Insights Epidemiology And Market Forecast

DelveInsight's 'Lyme disease (LD)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Lyme disease (LD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lyme disease (LD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028


Lyme disease (LD) - Disease Understanding and Treatment Algorithm

Lyme disease (LD) is caused by the spirochete Borrelia burgdorferi, injected into the blood stream after an infected tick has been attached 48-72 hrs. It is the most common vector-borne disease. The clinical presentation varies depending on the stage of the illness and includes erthyma migrans, carditis, central nervous system disease, and arthritis. Regardless of the clinical presentation, most patients with Lyme disease (LD) have resolution of their clinical symptoms when treated with appropriate antimicrobials. Persistent symptoms after therapy are most often due to misdiagnosis rather than treatment failure.

It can manifest as early localized disease (erythema migrans), early disseminated disease (e.g meningitis or multiple erythema migrans), or late disease (large joint arthritis). Both the innate and adaptive immune systems contribute to the inflammatory response which results in clinical symptoms. Regardless of the clinical presentation, the vast majority of patients who are treated for Lyme disease (LD) with short courses of appropriate antibiotics do extremely well.

The DelveInsight Lyme disease (LD) market report gives the thorough understanding of the Lyme disease (LD) by including details such as disease definition, disease microbiology, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Lyme disease (LD) in the US, Europe, and Japan.


Lyme disease (LD) Epidemiology

The Lyme disease (LD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as total incident population of Lyme disease (LD), gender specific incidence of Lyme disease (LD), total diagnosed population of Lyme disease (LD), acute and chronic incidence of Lyme disease (LD) and age specific diagnosed incidence of Lyme disease (LD)] scenario of Lyme disease (LD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2028.

According to DelveInsight, total incident population of Lyme disease (LD) in the 7 major markets is estimated approximately 489,605 cases in 2017 and it is expected to change in 2028.

DelveInsight estimates that the Incident population of Lyme disease (LD) will significantly change during the study period [2017-2028].

DelveInsight estimates suggest higher diagnosed incidence of Lyme disease (LD) in the United States with 280,152 diagnosed cases in 2017.


Lyme disease (LD) Drug Chapters

This segment of the Lyme disease (LD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, the therapeutic options comprises the use of antibiotics for the treatment of Lyme disease (LD). The present market does not holds any approved drug for Lyme disease (LD). The situation is equally crucial for the emerging therapies. The thin pipeline activities in this space makes the situation even more complicated. In the current scenario, the pipeline holds only one active product, VLA15 being developed by Valneva.

Expected Launch of potential therapies (currently only one i.e., VLA15) may increase market size in the coming years, assisted by an increase in diagnosed incident population of Lyme disease (LD). Owing to the positive outcomes during the early stage trials along with the Fast track Designation the only upcoming therapy VLA15 by Valneva has a potential to create a significant positive shift in the Lyme disease (LD) Market Size.

The treatment course for Lyme disease (LD) includes Antibiotics comprising Tetracycline (Doxycycline), Penicillins (Amoxicillin and Benzathine Penicillin), Cephalosporins (Cefuroxime, Ceftriaxone and Cefotaxime), Macrolides (Azithromycin and clarithromycin) and some other medications for the related manifestations associated with the Lyme disease (LD).

The First Line of Treatment for Lyme borreliosis comprises of Tetracycline, Penicillins followed by Cephalosporins.


Lyme disease (LD) Market Outlook

The Lyme disease (LD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Lyme disease (LD) in 7MM was found to be 403.64 million in 2017, and is expected to increase from 2017-2028.

The United States accounts for the largest market size of Lyme disease (LD) in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Lyme disease (LD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Lyme disease (LD) Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Lyme disease (LD) Report Key Strengths

• 10 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Key Cross Competition

• Highly Analyzed Market

• Drugs Uptake


Lyme disease (LD) Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Lyme disease (LD) market

• Organize sales and marketing efforts by identifying the best opportunities for Lyme disease (LD) market

• To understand the future market competition in the Lyme disease (LD) market. 


1. Key Insights    

2. Lyme disease (LD) Market Overview at a Glance    

2.1. Market Share (%) Distribution of Lyme disease (LD) in 2018    

2.2. Market Share (%) Distribution of Lyme disease (LD) in 2028    

3. Disease Background and Overview: Lyme disease (LD)    

3.1. Introduction    

3.2. Microbiology    

3.3. Transmission    

3.4. Clinical Manifestations    

3.4.1. Early Localized Disease    

3.4.2. Early Disseminated Disease    

3.4.3. Late Disease    

3.5. Risk of Lyme disease (LD)    

3.6. Pathogenesis    

3.7. Diagnosis    

3.8. Misdiagnosis    

3.9. Differential Diagnosis    

3.10. Prognosis    

3.10.1. Early Localized Disease    

3.10.2. Early disseminated Lyme disease (LD) (< 3 months)    

3.11. Post-Treatment Lyme disease (LD) Syndrome (PTLDS)    

3.12. Prevention    

4. Epidemiology and Patient Population    

4.1. Key Findings    

5. 7MM    

5.1.1. 7MM Total Incident Patient Population of Lyme disease (LD)    

5.1.2. 7MM Total Diagnosed Patient Population of Lyme disease (LD)    

6. Country Wise-Epidemiology of Lyme disease (LD)    

6.1. United States    

6.1.1. Assumptions and Rationale    

6.1.2. Total Incident Population of Lyme disease (LD) in the United States    

6.1.3. Gender Specific Incidence of Lyme disease (LD) in the United States    

6.1.4. Total Diagnosed Population of Lyme disease (LD) in the United States    

6.1.5. Acute and Chronic Incidence of Lyme disease (LD) in the United States    

6.1.6. Age Specific Diagnosed Incidence of Lyme disease (LD) in the United States    

6.2. EU5 Countries    

6.3. Germany    

6.3.1. Assumptions and Rationale    

6.3.2. Total Incidence of Lyme disease (LD) in Germany    

6.3.3. Gender Specific Incidence of Lyme disease (LD) in Germany    

6.3.4. Total Diagnosed Population of Lyme disease (LD) in Germany    

6.3.5. Acute and Chronic Incidence of Lyme disease (LD) in Germany    

6.3.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in Germany    

6.4. France    

6.4.1. Assumptions and Rationale    

6.4.2. Total Incidence of Lyme disease (LD) in France    

6.4.3. Gender Specific Incidence of Lyme disease (LD) in France    

6.4.4. Total Diagnosed Population of Lyme disease (LD) in France    

6.4.5. Acute and Chronic Incidence of Lyme disease (LD) in France    

6.4.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in France    

6.5. Italy    

6.5.1. Assumptions and Rationale    

6.5.2. Total Incident Population of Lyme disease (LD) in Italy    

6.5.3. Gender Specific Incidence of Lyme disease (LD) in Italy    

6.5.4. Total Diagnosed Population of Lyme disease (LD) in Italy    

6.5.5. Acute and Chronic Incidence of Lyme disease (LD) in Italy    

6.5.6. Age Specific Diagnosed Incidence of Lyme disease (LD) in Italy    

6.6. Spain    

6.6.1. Assumptions and Rationale    

6.6.2. Total Incident Population of Lyme disease (LD) in the United Kingdom    

6.6.3. Gender Specific Incidence of Lyme disease (LD) in Spain    

6.6.4. Total Diagnosed Population of Lyme disease (LD) in Spain    

6.6.5. Acute and Chronic Incidence of Lyme disease (LD) in Spain    

6.6.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in Spain    

6.7. United Kingdom    

6.7.1. Assumptions and Rationale    

6.7.2. Total Incident Population of Lyme disease (LD) in the United Kingdom    

6.7.3. Gender Specific Incidence of Lyme disease (LD) in the United Kingdom    

6.7.4. Total Diagnosed Population of Lyme disease (LD) in the United Kingdom    

6.7.5. Acute and Chronic Incidence of Lyme disease (LD) in the United Kingdom    

6.7.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in the United Kingdom    

6.8. Japan    

6.8.1. Assumptions and Rationale    

6.8.2. Total Incident Population of Lyme disease (LD) in Japan    

6.8.3. Gender Specific Incidence of Lyme disease (LD) in Japan    

6.8.4. Total Diagnosed Population of Lyme disease (LD) in Japan    

6.8.5. Acute and Chronic Incidence of Lyme disease (LD) in Japan    

6.8.6. Age Specific Diagnosed Incidence of Lyme disease (LD) in Japan    

7. Treatment    

7.1. Early localized disease (< 30 days)    

7.2. Early disseminated Lyme disease (LD) (< 3 months)    

7.3. Late Lyme disease (LD) (> 3 months)    

8. United States Guideline on Lyme disease (LD)    

9. European Guideline on Lyme disease (LD)    

9.1. Adults and Young People (aged 12 and over)    

9.2. In Children (Under 12)    

10. Unmet Needs    

11. Emerging Drugs    

11.1. Key Cross Competition    

11.2. VLA15: Valneva    

11.2.1. Product Description    

11.2.2. Other Developmental Activities    

11.2.3. Clinical Development    

11.2.4. Safety and Efficacy    

11.2.5. Advantages and Disadvantages    

11.2.6. Product Profile    

12. Lyme disease (LD): 7 Major Market Analysis    

12.1. Key Findings    

12.2. Market Size of Lyme disease (LD) in 7MM    

13. The United States Market Outlook    

13.1. United States Market Size    

13.2. Total Market size of Lyme disease (LD)    

13.3. Market Size by Therapies    

14. EU-5 Countries: Market Outlook    

14.1. Germany    

14.1.1. Total Market size of Lyme disease (LD) in Germany    

14.1.2. Market Size by Emerging Therapies    

14.2. France    

14.2.1. Total Market size of Lyme disease (LD)    

14.2.2. Market Size by Emerging Therapies    

14.3. Italy    

14.3.1. Total Market size of Lyme disease (LD)    

14.3.2. Market Size by Emerging Therapies    

14.4. Spain    

14.4.1. Total Market size of Lyme disease (LD)    

14.4.2. Market Size by Emerging Therapies    

14.5. United Kingdom    

14.5.1. Total Market size of Lyme disease (LD)    

14.5.2. Market Size by Emerging Therapies    

15. Japan: Market Outlook    

15.1. Japan market Size    

15.2. Total Market size of Lyme disease (LD)    

15.3. Market Size by Emerging Therapies    

16. Market Drivers    

17. Market Barriers    

18. Appendix    

18.1. Report Methodology    

19. DelveInsight Capabilities    

20. Disclaimer    

21. About DelveInsight   

Table 1: Distribution of GENOSPECIES of B. BURGDORFERI SL AND vectors of Lyme disease (LD) in different regions.

Table 2: Potential COINFECTIONS with Lyme disease (LD)

Table 3: Clinical Presentations and Therapy for Lyme disease (LD)

Table 4: Signs and Symptoms for Lyme disease (LD)

Table 5: Criteria and recommended prophylaxis after a tick bite

Table 6: Risk factors

Table 7: Diagnosis of clinical skin manifestations

Table 8: Predictive value of serologic tests vary by disease prevalence

Table 9: Differential Diagnosis of Erythema Migrans

Table 10: Risk factors for Post-Treatment Lyme disease (LD) Syndrome

Table 11: Total Incident Population of Lyme disease (LD) in the 7MM (2017-2028)

Table 12: Total Diagnosed Population of Lyme disease (LD) in the 7MM (2017-2028)

Table 13: Total Incident Population of Lyme disease (LD) in the United States (2017-2028)

Table 14: Gender specific Incidence of Lyme disease (LD) in the United States (2017-2028)

Table 15: Total Diagnosed Population of Lyme disease (LD) in the United States (2017-2028)

Table 16: Acute and Chronic Incidence of Lyme disease (LD) in the United States (2017-2028)

Table 17: Age Specific Diagnosed Incidence of Lyme disease (LD) in the United States (2017-2028)

Table 18: Total Incidence of Lyme disease (LD) in Germany (2017-2028)

Table 19: Gender specific Incidence of Lyme disease (LD) in Germany (2017-2028)

Table 20: Total Diagnosed Population of Lyme disease (LD) in Germany (2017-2028)

Table 21: Acute and Chronic Incidence of Lyme disease (LD) in Germany (2017-2028)

Table 22: Age Specific Diagnosed Incidence of Lyme disease (LD) in Germany (2017-2028)

Table 23: Total Incident Population of Lyme disease (LD) in France (2017-2028)

Table 24: Gender specific Incidence of Lyme disease (LD) in France (2017-2028)

Table 25: Total Diagnosed Population of Lyme disease (LD) in France (2017-2028)

Table 26: Acute and Chronic Incident Population of Lyme disease (LD) in France (2017-2028)

Table 27: Age Specific Diagnosed Incidence of Lyme disease (LD) in France(2017-2028)

Table 28: Total Incidence of Lyme disease (LD) in Italy (2017-2028)

Table 29: Gender specific Incidence of Lyme disease (LD) in Italy (2017-2028)

Table 30: Total Diagnosed Population of Lyme disease (LD) in Italy (2017-2028)

Table 31: Acute and Chronic Incidence of Lyme disease (LD) in Italy (2017-2028)

Table 32: Age Specific Diagnosed Incidence of Lyme disease (LD) in Italy (2017-2028)

Table 33: Total Incidence of Lyme disease (LD) in Spain (2017-2028)

Table 34: Gender specific Incidence of Lyme disease (LD) in Spain(2017-2028)

Table 35: Total Diagnosed Population of Lyme disease (LD) in Spain (2017-2028)

Table 36: Acute and Chronic Incidence of Lyme disease (LD) in Spain (2017-2028)

Table 37: Age Specific Diagnosed Incidence of Lyme disease (LD) in Spain (2017-2028)

Table 38: Total Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Table 39: Gender specific Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Table 40: Total Diagnosed Population of Lyme disease (LD) in the United Kingdom (2017-2028)

Table 41: Acute and Chronic Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Table 42: Age Specific Diagnosed Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Table 43: Total Incident Population of Lyme disease (LD) in Japan (2017-2028)

Table 44: Gender specific Incidence of Lyme disease (LD) in Japan (2017-2028)

Table 45: Total Diagnosed Population of Lyme disease (LD) in Japan (2017-2028)

Table 46: Acute and Chronic Incidence of Lyme disease (LD) in Japan (2017-2028)

Table 47: Age Specific Diagnosed Incidence of Lyme disease (LD) in Japan (2017-2028)

Table 48: Clinical Presentations and Therapy for Lyme disease (LD)

Table 49: Antibiotic regimens for Lyme disease (LD)

Table 50: Treatment Guideline of Lyme disease (LD)

Table 51: Antibiotic treatment for Lyme disease (LD) in adults and young people (aged 12 and over) according to symptoms

Table 52: Antibiotic treatment for Lyme disease (LD) in children (under 12) according to symptoms

Table 53: Comparison of emerging drugs under development

Table 54: VLA15, Clinical Trial Description, 2018

Table 55: 7 Major Market Size of Lyme disease (LD) in USD Million (2017-2028)

Table 56: United States Market Size of Lyme disease (LD) in USD Million (2017-2028)

Table 57: Market size of Lyme disease (LD) by therapies in United States, in USD Million (2017-2028)

Table 58: Market Size of Lyme disease (LD) in Germany, in USD Million (2017-2028)

Table 59: Market Size of Lyme disease (LD) by therapies in Germany, in USD Million (2017-2028)

Table 60: Market Size of Lyme disease (LD) in France, in USD Million (2017-2028)

Table 61: Emerging Therapies market of Lyme disease (LD) in France, in USD Million (2017-2028)

Table 62: Market Size of Lyme disease (LD) in Italy, in USD Million (2017-2028)

Table 63: Market Size of Lyme disease (LD) by therapies in Italy, in USD Million (2017-2028)

Table 64: Market Size of Lyme disease (LD) in Spain, in USD Million (2017-2028)

Table 65: Market Size of Lyme disease (LD) by therapies in Spain, in USD Million (2017-2028)

Table 66: Market Size of Lyme disease (LD) in the UK, in USD Million (2017-2028)

Table 67: Market Size of Lyme disease (LD) by therapies in the UK, in USD Million (2017-2028)

Table 68: Market Size of Lyme disease (LD) in Japan, in USD Million (2017-2028)

Table 69: Market Size of Lyme disease (LD) by therapies in Japan, in USD Million (2017-2028)

Figure 1: Geographical distribution of the Ixodes tick vectors of the spirochetes that cause Lyme disease (LD)

Figure 2: Two-year lifecycle of IXODID ticks

Figure 3: Diagnostic Algorithm for Lyme disease (LD)

Figure 4: Total Incident Patient Population of Lyme disease (LD) in the 7MM (2017-2028)

Figure 5: Total Diagnosed Patient Population of Lyme disease (LD) in the 7MM (2017-2028)

Figure 6: Incidence of Lyme disease (LD) in the United States (2017-2028)

Figure 7: Gender Specific Incidence of Lyme disease (LD) in the United States (2017-2028)

Figure 8: Diagnosed Population of Lyme disease (LD) in the United States (2017-2028)

Figure 9: Acute and Chronic Incidence of Lyme disease (LD) in the United States (2017-2028)

Figure 10: Age Specific Diagnosed Incidence of Lyme disease (LD) in the United States (2017-2028)

Figure 11: Incidence of Lyme disease (LD) in Germany (2017-2028)

Figure 12: Gender Specific Incidence of Lyme disease (LD) in Germany (2017-2028)

Figure 13: Diagnosed Population of Lyme disease (LD) in Germany (2017-2028)

Figure 14: Acute and Chronic Incident Population of Lyme disease (LD) in Germany (2017-2028)

Figure 15: Age Specific Diagnosed Incidence of Lyme disease (LD) in Germany (2017-2028)

Figure 16: Incidence of Lyme disease (LD) in France (2017-2028)

Figure 17: Gender Specific Incidence of Lyme disease (LD) in France (2017-2028)

Figure 18: Diagnosed Population of Lyme disease (LD) in France (2017-2028)

Figure 19: Acute and Chronic Incidence of Lyme disease (LD) in France (2017-2028)

Figure 20: Age Specific Diagnosed Incidence of Lyme disease (LD) in France (2017-2028)

Figure 21: Incidence of Lyme disease (LD) in Italy (2017-2028)

Figure 22: Gender Specific Incidence of Lyme disease (LD) in Italy (2017-2028)

Figure 23: Diagnosed Population of Lyme disease (LD) in Italy (2017-2028)

Figure 24: Acute and Chronic Incidence of Lyme disease (LD) in Italy (2017-2028)

Figure 25: Age Specific Diagnosed Incidence of Lyme disease (LD) in Italy (2017-2028)

Figure 26: Incidence of Lyme disease (LD) in Spain (2017-2028)

Figure 27: Gender Specific Incidence of Lyme disease (LD) in Spain (2017-2028)

Figure 28: Diagnosed Population of Lyme disease (LD) in Spain (2017-2028)

Figure 29: Acute and Chronic Incidence of Lyme disease (LD) in Spain (2017-2028)

Figure 30: Age Specific Diagnosed Incidence of Lyme disease (LD) in Spain (2017-2028)

Figure 31: Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Figure 32: Gender Specific Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Figure 33: Diagnosed Population of Lyme disease (LD) in the United Kingdom (2017-2028)

Figure 34: Acute and Chronic Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Figure 35: Age Specific Diagnosed Incidence of Lyme disease (LD) in the United Kingdom (2017-2028)

Figure 36: Incidence of Lyme disease (LD) in Japan (2017-2028)

Figure 37: Gender Specific Incidence of Lyme disease (LD) in Japan (2017-2028)

Figure 38: Diagnosed Population of Lyme disease (LD) in Japan (2017-2028)

Figure 39: Acute and Chronic Incident Population of Lyme disease (LD) in Japan (2017-2028)

Figure 40: Age Specific Diagnosed Incidence of Lyme disease (LD) in Japan (2017-2028)

Figure 41: Diagnostic Algorithm for Lyme disease (LD)

Figure 42: Unmet Needs of Lyme disease (LD)

Figure 43: 7 Major Market Size of Lyme disease (LD) in USD Million (2017-2028)

Figure 44: Market Size of Lyme disease (LD) in the United States, USD Millions (2017-2028)

Figure 45: Market size of Lyme disease (LD) by therapies in the US, in USD Million (2017-2028)

Figure 46: Market Size of Lyme disease (LD) in Germany, USD Millions (2017-2028)

Figure 47: Market Size of Lyme disease (LD) by therapies, in Germany, in USD Million (2017-2028)

Figure 48: Market Size of Lyme disease (LD) in France, USD Millions (2017-2028)

Figure 49: Market Size of Lyme disease (LD) by therapies, in France, in USD Million (2017-2028)

Figure 50: Market Size of Lyme disease (LD) in Italy, USD Millions (2017-2028)

Figure 51: Market Size of Lyme disease (LD) by therapies in Italy, in USD Million (2017-2028)

Figure 52: Market Size of Lyme disease (LD) in Spain, USD Millions (2017-2028)

Figure 53: Market Size of Lyme disease (LD) by therapies in Spain, in USD Million (2017-2028)

Figure 54: Market Size of Lyme disease (LD) in the UK, USD Millions (2017-2028)

Figure 55: Market Size of Lyme disease (LD) by therapies in the UK, in USD Million (2017-2028)

Figure 56: Market Size of Lyme disease (LD) in Japan, USD Millions (2017-2028)

Figure 57: Market Size of Lyme disease (LD) by therapies in Japan, in USD Million (2017-2028)

Figure 58: Market Drivers

Figure 59: Market Barriers

  • Tags:
  • Lyme disease (LD) market
  • Lyme disease (LD) market research
  • Lyme disease (LD) market insight
  • Lyme disease (LD) market trends
  • Lyme disease (LD) market forecast
  • Lyme disease (LD) market share
  • Lyme disease (LD) pipeline drugs
  • Lyme disease (LD) treatment algorit...
  • Lyme disease (LD) drugs
  • Lyme disease (LD) sales forecasting
  • Lyme disease (LD) market size
  • Lyme disease (LD) disease
  • Lyme disease (LD) epidemiology
  • Lyme disease (LD)
  • Lyme disease (LD) Companies
  • Lyme disease (LD) Pipeline

Forward to Friend

Need A Quote